Physician profile
Michael King
NPI 1861434086
$13,743.02
in general payments reported to CMS, 2019-2025
33 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $961 · 2021: $1,929 · 2022: $1,854 · 2023: $2,487 · 2024: $2,470 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,393 · Education: $41.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,392.69 |
| Education | $41.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,222.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,030.00 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $1,935.86 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Glaxosmithkline, LLC. | $1,595.27 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $789.95 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $689.12 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $638.08 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $572.56 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Pharming Healthcare, INC. | $451.55 | 2019-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $357.95 | 2021-2024 | Orladeyo |
| Phathom Pharmaceuticals, INC. | $355.74 | 2024 | Voquezna |
| Amgen INC. | $355.20 | 2022-2025 | Tezspire, Actimmune |
| Blueprint Medicines Corporation | $274.14 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $244.25 | 2019-2025 | |
| Kaleo, INC. | $210.92 | 2019-2024 | Auvi-Q |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $142.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $130.39 | 2019-2022 | |
| Octapharma USA, INC. | $129.37 | 2019-2024 | Cutaquig |
| Optinose US, INC. | $128.47 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.33 | 2019 | |
| Aimmune Therapeutics, INC. | $91.91 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $53.04 | 2025 | Neffy |
| Biocryst Pharmaceuticals, INC. | $39.87 | 2020 | |
| Ionis Pharmaceuticals, INC. | $39.00 | 2025 | Dawnzera |
| Lilly USA, LLC | $24.28 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $23.52 | 2023 | |
| Galderma Laboratories, L.P. | $22.68 | 2025 | Nemluvio |
| Bio Products Laboratory USA, INC. | $20.04 | 2023 | Gammaplex, Coagadex |
| Uswm, LLC | $17.00 | 2021 | |
| Alk-Abello, INC | $16.82 | 2023 | Grastek, Ragwitek, Odactra |
| Abbvie INC. | $16.09 | 2022 | |
| Phadia US INC. | $12.88 | 2022 | |
| Shire North American Group INC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.